A combined diphtheria, tetanus, five-component acellular pertussis, poliovirus and Haemophilus influenzae type b vaccine

References

• Centers for Disease Control and Prevention. Combination vaccines for childhood immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP), the American Academy of Pediatrics (AAP), and the American Academy of Family Physicians (AAFP). Morb. Mortal. Wkly Rep. 48(RR-5), 1–15 (1999).
   PubMedGoogle Scholar
• National Advisory Committee on Immunization (NACI). Interchangeability of diphtheria, tetanus, acellular pertussis, polio, Haemophilus influenzae type b combination vaccines presently approved for use in Canada for children <7 years of age. Can. Commun. Dis. Rep. 31, 1–10 (2005).
   Google Scholar
• Mills E, Gold R, Thipphawong J et al. Safety and immunogenicity of a combined five-component pertussis–diphtheria–tetanus-inactivated poliomyelitis–Haemophilus b conjugate vaccine administered to infants at two, four and six months of age. Vaccine 16, 576–585 (1998).
   PubMed Web of Science ®Google Scholar
• Black S, Shinefield H; the 494–01/00 Collaborative Investigators Group. Safety of DTaP–IPV//PRP-T (Pentacel™) as compared to the administration of component vaccines in different injection sites. The 3rd Pediatric Infectious Disease Conference. Monterey, CA, USA. October 2001 (2001) (Abstract).
   Google Scholar
• Blatter MM, Noriega F. Immunogenicity and safety of Pentacel™ (diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b vaccine) in US infants 2, 4, and 6 months of age. The 11th International Congress on Infectious Diseases. Cancun, Mexico, March 2004 (2004)(Abstract).
   Google Scholar
• Noriega F, Tomovici A, Jemiolo D, Greenberg DP, P3T06 study group. Safety and immunogenicity comparison of a fourth dose of DTaP–IPV//PRP-T (Pentacel™) to the separate administration of Daptacel® and ActHIB®. The 43rd Annual Meeting of the Infectious Diseases Society of America. San Francisco, USA. October, 2005. (2005) (Abstract No 985).
   Google Scholar
• Noriega F, Tsang P, Jemiolo D, Voloshen T, Greenberg DP; the Pentacel Investigators Study Group. Immunogenicity of a four dose series of DTaP–IPV//PRP-T (Pentacel™). The 5th Pediatric Infectious Disease Conference. Napa, CA, USA. October, 2005. (2005)(Abstract No 9).
   Google Scholar
• Herz A, Black S, Shinefield H, Noriega F, Greenberg D. Safety of Combined DTaP–IPV + PRP-T (Pentacel™) administered at 2, 4, 6, and 15 to 18 months of age. The Pediatric Academic Societies Annual Meeting. Washington DC, USA. May 2005. (2005)(Abstract No 1388).
   Google Scholar
• Decker MD. Principles of pediatric combination vaccines and practical issues related to use in clinical practice. Pediatr. Infect. Dis. J. 20(Suppl. 11), S10–S18 (2001).
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention. Recommended childhood and adolescent immunization schedule - United States, 2005. Morb. Mortal. Wkly Rep. 53, Q1-Q3 (2004).
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention. Vaccination coverage among children entering school – United States, 2003–2004 school year. Morb. Mortal. Wkly Rep. 53, 1041–1044 (2004).
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention. National, state, and urban area vaccination coverage among children aged 19–35 months - United States, 2003. Morb. Mortal. Wkly Rep. 53, 658–661 (2004).
   PubMedGoogle Scholar
• Frenkel LD, Nielsen K. Immunization issues for the 21st century. Ann. Allergy Asthma Immunol. 90(6 Suppl. 3), 45–52 (2003).
   PubMedGoogle Scholar
• Vidor E, Hoffenbach A, Fletcher MA. Haemophilus influenzae type b vaccine: reconstitution of lyophilised PRP-T vaccine with a pertussis-containing paediatric combination vaccine, or a change in the primary series immunisation schedule, may modify the serum antiPRP antibody responses. Curr. Med. Res. Opin. 17, 97–209 (2001).
   Google Scholar
• Schmitt HJ, Zepp F, Muschenborn S et al. Immunogenicity and reactogenicity of a Haemophilus influenzae type b tetanus conjugate vaccine when administered separately or mixed with concomitant diphtheria-tetanus-toxoid and acellular pertussis vaccine for primary and for booster immunizations. Eur. J. Pediatr. 157, 208–214 (1998).
   PubMed Web of Science ®Google Scholar
• Eskola J, Ward J, Dagan R, Goldblatt D, Zepp F, Siegrist CA. Combined vaccination of Haemophilus influenzae type b conjugate and diphtheria-tetanus-pertussis containing acellular pertussis. Lancet 354, 2063–2068 (1999).
   PubMed Web of Science ®Google Scholar
• Halperin SA, King J, Law B, Mills E, Willems P. Safety and immunogenicity of Haemophilus influenzae-tetanus toxoid conjugate vaccine given separately or in combination with a three-component acellular pertussis vaccine combined with diphtheria and tetanus toxoids and inactivated poliovirus vaccine for the first four doses. Clin. Infect. Dis. 28, 995–1001 (1999).
   PubMed Web of Science ®Google Scholar
• Daum RS, Zenko CE, Given GZ, Ballanco GA, Parikh H, Germino K. Magnitude of interference after diphtheria-tetanus toxoids-acellular pertussis/Haemophilus influenzae type b capsular polysaccharide-tetanus vaccination is related to the number of doses administered. J. Infect. Dis. 184, 1293–1299 (2001).
   PubMed Web of Science ®Google Scholar
• Edwards KM, Decker MD. Combination vaccines. Infect. Dis. Clin. North Am. 15, 209–230 (2001).
   PubMedGoogle Scholar
• McVernon J, Andrews N, Slack MP, Ramsay ME. Risk of vaccine failure after Haemophilus influenzae type b (Hib) combination vaccines with acellular pertussis. Lancet 361, 1521–1523 (2003).
   PubMed Web of Science ®Google Scholar
• Kalies H, Verstaeten T, Grote V et al. Four and one-half-year follow-up of the effectiveness of diphtheria-tetanus toxoids-acellular pertussis/Haemophilus influenzae type b and diphtheria-tetanus toxoids-acellular pertussis-inactivated poliovirus/H. influenzae type b combination vaccines in Germany. Pediatr. Infect. Dis. J. 23, 944–950 (2004).
   PubMed Web of Science ®Google Scholar
• Gonzalez SN, Aguilar F, Barreto L, Muller C, Castaneda JL, Chavez R. A fully immunogenic pentavalent combination vaccine (DTaP-IPV and PRP-T). The 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA. September 1999. (1999) (Abstract No 238).
   Google Scholar
• Lee CY, Thipphawong J, Huang LM et al. An evaluation of the safety and immunogenicity of a five-component acellular pertussis, diphtheria, and tetanus toxoid vaccine (DTaP) when combined with a Haemophilus influenzae type b-tetanus toxoid conjugate vaccine (PRP-T) in Taiwanese infants. Pediatrics 103, 25–30 (1999).
   PubMed Web of Science ®Google Scholar
• FDA licensure of diphtheria and tetanus toxoids and acellular pertussis adsorbed, hepatitis B (recombinant), and poliovirus vaccine combined, (Pediarix) for use in infants. Morb. Mortal. Wkly Rep. 52, 203–204 (2003).
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention. Acute hepatitis B among children and adolescents - United States, 1990–2002. Morb. Mortal. Wkly Rep. 53, 1015–1018 (2004).
   PubMedGoogle Scholar
• Zepp F, Schuind A, Meyer C, Sanger R, Kaufhold A, Willems P. Safety and reactogenicity of a novel DTPa–HBV–IPV combined vaccine given along with commercial Hib vaccines in comparison with separate concomitant administration of DTPa, Hib, and OPV vaccines in infants. Pediatrics 109, E58 (2002).
   Google Scholar
• Pediarix Prescribing information, GlaxoSmithKline, August (2003).
   Google Scholar
• Thompson LA, Irigoyen M, Matiz LA, LaRussa PS, Chen S, Chimkin F. Infant age and untoward effects of the newest immunization schedule. The Pediatric Academic Societies’ Annual Meeting. Washington, DC, USA. May 2005. Pediatr. Res. 57, (2005)(Abstract No 861).
   Google Scholar
• Edwards KM. Development, acceptance, and use of immunologic correlates of protection in monitoring the effectiveness of combination vaccines. Clin. Infect. Dis. 33(Suppl. 4), S274–S277 (2001).
   PubMed Web of Science ®Google Scholar
• Greenberg DP, Scheifele D, Noriega F. Immunogenicity of Pentacel™ when administered as a fourth dose at 15 to 18 months of age. The Pediatric Academic Societies’ Annual Meeting. San Francisco, CA, USA. May 2004. (2004)(Abstract LB18).
   Google Scholar
• Edwards KM, Tsang P, Wang, L, and Noriega, F for the M5A03 Study Group. Safety and Immunogenicity of DTaP-IPV//PRP-T (Pentacel™) Coadministered with Pneumococcal Conjugate Vaccine (Prevnar®) at 2, 4, and 6 months of age. The 43rd Annual Meeting of the Infectious Diseases Society of America. San Francisco, USA, October, 2005. (2005)(Abstract No 984).
   Google Scholar
• Noriega F, Greenberg DP, Tsang PH et al. Effect of pneumococcal conjugate vaccine (PCV-7) on antibody responses to concomitantly administered Pentacel™ (DTaP-IPV//PRP-T) or licensed equivalent vaccines. The 43rd Annual Meeting of Infectious Diseases Society of America. San Francisco, USA, October, 2005 (2005)(Abstract No 981).
   Google Scholar
• Halperin SA, McDonald J, Samson L et al. Simultaneous administration of meningococcal C conjugate vaccine and diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine in children: a randomized double-blind study. Clin. Invest. Med. 25, 243–51 (2002).
   PubMed Web of Science ®Google Scholar
• Halperin BA, Halperin SA, McGrath P, Smith B, Houston T. Use of lidocaine-prilocaine patch to decrease intramuscular injection pain does not adversely affect the antibody response to diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b conjugate and hepatitis B vaccines in infants from birth to six months of age. Pediatr. Infect. Dis. J. 21, 399–405 (2002).
   PubMed Web of Science ®Google Scholar
• Gustafsson L, Hallander HO, Olin P, Reizenstein E, Storsaeter, J. A controlled trial of a two-component acellular, a five-component acellular and a whole-cell pertussis vaccine. N. Engl. J. Med. 334, 349–355 (1996).
   PubMed Web of Science ®Google Scholar
• Storsaeter J, Hallander HO, Gustafsson L, Olin P. Levels of antipertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine 16, 1907–1916 (1998).
   PubMed Web of Science ®Google Scholar
• Olin P, Rasmussen F, Gustafsson L, Hallander HO, Heijbel H. Randomised controlled trial of two-component, three component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Ad Hoc group for the study of pertussis vaccines. Lancet. 350, 1569–1577 (1997).
   PubMed Web of Science ®Google Scholar
• Casey JR, Pichichero ME. Acellular pertussis vaccine safety and efficacy in children, adolescents and adults. Drugs 65(10), 1367–1389 (2005).
   PubMed Web of Science ®Google Scholar
• Skowronski DM, Remple VP, Macnabb J et al. Injection-site reactions to booster doses of acellular pertussis vaccine: rate, severity, and anticipated impact. Pediatrics 112, 453–459 (2003).
   PubMed Web of Science ®Google Scholar
• Le Saux N, Barrowman NJ, Moore DL, Whiting S, Scheifele D, Halperin, S. Decrease in hospital admissions for febrile seizures and reports of hypotonic-hyporesponsive episodes presenting to hospital emergency departments since switching to acellular pertussis vaccine in Canada: a report from IMPACT. Pediatrics 112, E348 (2003).
   Google Scholar
• Skowronski DM, Patrick DM, Naus M et al. Survey for Serious Adverse Events (SAEs) Following Immunization with the 4th dose of a diphtheria, tetanus, acellular pertussis, inactivated poliovirus and Haemophilus influenzae type b Combination Vaccine (DTaP-IPV//PRP-T, Pentacel™) in British Columbia (BC), Canada. The 43rd Annual Meeting of the Infectious Diseases Society of America. San Francisco, USA. October, 2005. (2005)(Abstract No 988).
   Google Scholar
• Scheifele D, Halperin S. Haemophilus influenzae type b disease control using Pentacel™, Canada, 1998–1999. Can. Commun. Dis. Rep. 26, 93–96 (2000).
   PubMedGoogle Scholar
• Scheifele D, Halperin S, Law B, King A, Canadian Paediatric Society/Health Canada Immunization Monitoring Program, Active (IMPACT). Invasive Haemophilus influenzae type b infections in vaccinated and unvaccinated children in Canada, 2001–2003. Can. Med. Assoc. J. 172, 53–56 (2005).
   PubMed Web of Science ®Google Scholar
• Skowronski DM, De Serres G, MacDonald D et al. The changing age and seasonal profile of pertussis in Canada. J. Infect. Dis. 185, 1448–1453 (2002).
   PubMed Web of Science ®Google Scholar
• Kandola K, Lea A, White W, Santos M. A comparison of pertussis rates in Northwest Territories: pre-and post-acellular pertussis vaccine introduction in children and adolescents. The 6th Canadian Immunization Conference. Montreal, Quebec, Canada. December (2004).
   Google Scholar
• National Advisory Committee on Immunization (NACI). An Advisory Committee Statement (ACS). Prevention of pertussis in adolescents and adults. Can. Commun. Dis. Rep. 29, 1–9 (2003).
   Google Scholar
• Bettinger J, Halperin S, De Serres G, Scheifele D, IMPACT Investigators. Epidemiology of hospitalized pertussis after change from whole-cell to acellular pertussis vaccine. The Canadian Immunization Conference. Montreal, Quebec, Canada. December (2004).
   Google Scholar